At a glance
- Company
- Cardio Diagnostics Holdings
- Ticker
- NASDAQ: CDIO
- Announcement
- Partnership
- Location
- Los Angeles and Orange counties
Products and programs
, an AI-powered precision cardiovascular medicine company, announced that Atlas Healthcare Physicians, an independent physician association serving managed care populations across Los Angeles and Orange counties, will provide coverage for the company’s Epi+Gen CHD(TM) and PrecisionCHD(TM) tests for eligible members with prior authorization. The coverage expands access to physician-ordered blood tests designed to assess coronary heart disease risk and support diagnosis and personalized treatment planning.
Cardio Diagnostics said Epi+Gen CHD(TM) evaluates a patient’s three-year risk of a coronary heart disease event, while PrecisionCHD(TM) helps diagnose coronary heart disease and identify its underlying molecular drivers. The company noted that both tests are noninvasive blood-based diagnostics that do not require fasting or radiation exposure, supporting broader adoption of precision cardiovascular medicine across community healthcare networks.
To view the full press release, visit https://nnw.fm/EFQen
About Cardio Diagnostics
Cardio Diagnostics is an artificial intelligence-powered precision cardiovascular medicine company that makes cardiovascular disease prevention, detection, and management more accessible, personalized, and precise. The company was formed to further develop and commercialize clinical tests by leveraging a proprietary Artificial Intelligence (AI)-driven Integrated Genetic-Epigenetic Engine (“Core Technology”) for cardiovascular disease to become one of the leading medical technology companies for improving prevention, detection, and treatment of cardiovascular disease.
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to CDIO are available in the company’s newsroom at https://ibn.fm/CDIO
Corporate Communications
IBN
Austin, Texas
www.InvestorBrandNetwork.com
512.354.7000 Office
[email protected]
Questions around this news
What coverage did Atlas Healthcare Physicians announce for the cardiovascular tests?
Atlas Healthcare Physicians will provide coverage for Cardio Diagnostics’ Epi+Gen CHD and PrecisionCHD blood tests for eligible members, subject to prior authorization. The physician association serves managed care populations in Los Angeles and Orange counties. The announcement describes the coverage as expanding access to physician-ordered tests for assessing coronary heart disease risk and supporting diagnosis and treatment planning.
How do the Epi+Gen CHD and PrecisionCHD tests differ?
The release says Epi+Gen CHD evaluates a patient’s risk of a coronary heart disease event over three years. PrecisionCHD is described as helping diagnose coronary heart disease and identify molecular factors associated with it. Both are blood-based tests, but the stated purposes differ: one assesses risk, while the other supports diagnosis and identification of underlying molecular drivers.
What does prior authorization mean in health care?
Prior authorization is a review process in which a health plan or other payer evaluates a proposed service before it is provided or covered. The process may require information from a clinician about the patient and the medical reason for the service. Approval requirements and procedures vary by payer and plan; authorization does not necessarily guarantee payment in every circumstance.
Earlier from Cardio Diagnostics
- Cardio Diagnostics Holdings (NASDAQ: CDIO) Targets a $393B Heart Disease Problem with Epigenetics and AI
- Cardio Diagnostics Holdings (NASDAQ: CDIO) Offers Broad Suite of AI-Powered Solutions for Cardiovascular Disease Prevention
- Cardio Diagnostics Holdings (NASDAQ: CDIO) Advancing Early Detection, Tackling Heart Disease Through AI and Biomarker Insights
- Cardio Diagnostics Holdings (NASDAQ: CDIO) Is ‘One to Watch’
